Parallel Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Parallel Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.12K	Hold	83	–	–	﹤0.01%	3757
2026 Q2	$899	Hold	83	–	–	﹤0.01%	3705
2026 Q1	$1.05K	Hold	83	–	–	﹤0.01%	3535
2025 Q4	$679	Hold	83	–	–	﹤0.01%	3364
2025 Q3	$996	Hold	83	–	–	﹤0.01%	3220
2025 Q2	$842	Buy	+83	New	+$557	﹤0.01%	3228
2022 Q1	–	Sell	-628	Closed	-$9K	–	3183
2021 Q4	$9K	Buy	628 +626	+31,300%	+$9.8K	﹤0.01%	2164
2021 Q3	$0	Buy	+2	New	+$41	﹤0.01%	3212

Other funds holding ORIC

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Parallel Advisors's ORIC Position: Q3 2026 in Review

Parallel Advisors held its Oric Pharmaceuticals (ORIC) position steady in Q3 2026 at 83 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #3757.

Parallel Advisors first reported a position in ORIC in Q3 2021 and has held it in 8 quarters since. The position peaked at $9K in Q4 2021. 36 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

Parallel Advisors held 83 shares of Oric Pharmaceuticals worth $1.12K as of Q3 2026.
Parallel Advisors left its Oric Pharmaceuticals share count unchanged in Q3 2026.
Oric Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3757 holding.
Parallel Advisors first reported a position in Oric Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
Parallel Advisors's Oric Pharmaceuticals position peaked at $9K in Q4 2021.
36 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.